FOI_7816

Internal Reference Number: FOI_7816

Date Request Received: 12/03/2024 00:00:00

Date Request Replied To: 09/04/2024 00:00:00

This response was sent via: By Email

Request Summary: Oncology Supplemental

Request Category: Researcher


Question Number 1: How many patients were treated in the past 3 months for gastric and gastro-oesophageal junction cancer (any stage) with: • FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin) • Lonsurf (Trifluridine - tipiracil) • Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) • Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) • Any other systemic anti-cancer therapy • Palliative care only

Answer To Question 1: • FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin) 0 patients • Lonsurf (Trifluridine - tipiracil) 0 patients • Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) <5 patients • Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) 0 patients • Any other systemic anti-cancer therapy 5 patients • Palliative care only - unable to answer

Question Number 2: How many early-stage (non-metastatic or Stages 1-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with: • Atezolizumab (Tecentriq) • Durvalumab (Imfinzi) • Nivolumab (Opdivo) • Pembrolizumab (Keytruda) • Chemotherapy • Radiotherapy • Chemotherapy AND Radiotherapy

Answer To Question 2: • Atezolizumab (Tecentriq) <5 patients • Durvalumab (Imfinzi) <5 patients • Nivolumab (Opdivo) <5 patients • Pembrolizumab (Keytruda) <5 patients • Chemotherapy 7 patients • Radiotherapy - Radiotherapy not delivered at SFT. Unable to answer • Chemotherapy AND Radiotherapy - Radiotherapy not delivered at SFT. Unable to answer

Question Number 3: In the past three months, how many advanced renal cell carcinoma patients received the following first-line treatments: • Avelumab + Axitinib (Bavencio + Inlyta) • Cabozantinib (Cometriq) • Nivolumab (Opdivo) • Nivolumab + Cabozantinib (Opdivo + Cometriq) • Nivolumab + Ipilimumab (Opdivo + Yervoy) • Pembrolizumab + Lenvatinib (Keytruda + Kisplyx)

Answer To Question 3: 0 Patients treated. Renal cancer patients are not treated at Salisbury Hospital

To return to the list of all the FOI requests please click here

Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.